Antibiotic research and development: business as usual?

Area of Science:

• Microbiology
• Pharmacology
• Health Economics

Background:

• Antibiotic resistance is a growing global health crisis, necessitating new anti-infective strategies.
• Pharmaceutical companies are reducing investment in antibacterial drug discovery due to scientific challenges and diminishing economic incentives.
• Current economic factors, including stewardship initiatives and low antibiotic prices, deter new drug development.

Purpose of the Study:

• To address the urgent need for new antibiotics by exploring innovative economic models.
• To define standards for responsible antibiotic use.
• To incentivize investment in the development of novel anti-infective agents.

Main Methods:

• The DRIVE-AB consortium, a public-private partnership funded by the EU Innovative Medicines Initiative, is investigating new economic models.
• Development and testing of novel economic frameworks to stimulate antibacterial drug discovery.
• Defining best practices for responsible antibiotic utilization.

Main Results:

• Identification of key economic and regulatory hurdles in antibacterial drug development.
• Proposing new economic models to align incentives for antibiotic innovation with responsible use.
• Establishing a framework for responsible antibiotic stewardship.

Conclusions:

• New economic models are essential to overcome the financial barriers in antibiotic research and development.
• A balanced approach integrating economic incentives with responsible use is crucial for combating antibiotic resistance.
• The DRIVE-AB initiative aims to foster a sustainable ecosystem for anti-infective drug discovery and deployment.